Towards Healthcare Research & Consulting

Hearing Loss Gene Therapy Companies and Market Forecast

Date : 06 May 2026

Companies Offerings in the Hearing Loss Gene Therapy Market

Hearing Loss Gene Therapy Market Companies are Regeneron Pharmaceuticals, Akouos (Eli Lilly), Sensorion, Fudan University, Otovia Therapeutics

Company Description
Regeneron Pharmaceuticals It has unveiled Otarmeni (lunsotogene parvec-cwha), the first-ever FDA-approved gene therapy for genetic hearing loss.
Akouos (Eli Lilly) This firm leads in the development of Adeno-associated viral (AAV) vector-based gene therapies for inner ear issues.
Sensorion Its groundbreaking portfolio emphasizes SENS-501 for OTOF gene-mediated deafness.
Fudan University This mainly provides gene therapy treatments & clinical trials for hereditary hearing loss, especially for the rare condition DFNB9.
Otovia Therapeutics It has explored OTOV-101, an innovative dual adeno-associated virus (AAV) gene therapy.
Astellas Pharma This company facilitates a variety of regenerative medicine & in vivo gene therapy solutions to repair inner ear hair cells to treat sensorineural hearing loss.
BridgeBio Pharma Its offerings cover BBP-815, an investigational adeno-associated virus (AAV) gene therapy.

Latest Developments in the Hearing Loss Gene Therapy Market

  • In January 2026, Sensorion secured a €60m ($71.9m) to empower the development of its gene therapy pipeline.
  • In January 2026, Seamless Therapeutics collaborated with Eli Lilly and Company to establish & commercialize programmable recombinase-based genetic medicines targeting hearing loss.

Hearing Loss Gene Therapy Market- Supply Chain Analysis

R&D

  • With an emphasis on reversing hereditary hearing loss (HHL) by correcting underlying genetic mutations, firms are executing determination of targets, vector development, preclinical validation, delivery improvement, & clinical trials.  
  • Key Players: Regeneron Pharmaceuticals, Akouos (Eli Lilly), Sensorion, etc.

Clinical Trials & Regulatory Approvals

  • To achieve a regulatory approval, these trials cover extensive Patient Selection & Genetic Confirmation, delivery improvements, outcomes measures, and finally follow-up, coupled with monitoring.
  • Key Players: Akouos, Inc., Yilai Shu, Eye & ENT Hospital of Fudan University, etc.

Patient Support & Services

  • Organizations are facilitating genetic counseling, specialized surgical teams, & long-term rehabilitation to control & enhance restored hearing.
  • Key Players: HLAA, AG Bell Association, ACI Alliance, etc.

Market Growth

The global hearing loss gene therapy market size was estimated at USD 1.12 billion in 2025 and is predicted to increase from USD 1.33 billion in 2026 to approximately USD 6.32 billion by 2035, expanding at a CAGR of 18.9% from 2026 to 2035.

Hearing Loss Gene Therapy Market Size is USD 1.33 Billion in 2026.